Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings, Inc. reported a material cybersecurity incident after detecting unauthorized activity on certain third-party-hosted business applications on June 8, 2026. A threat actor later claimed to have obtained proprietary data, patient protected health information, and other personal information and demanded payment to avoid disclosure.
The company has confirmed that some data was exfiltrated but, as of this report, has not found any impact on its products, clinical or medical device systems, patient safety, operations, or financial reporting systems. The affected data was accessed via social engineering and did not involve clinical systems or individual financial account or payment card information.
iRhythm is continuing to investigate the nature and scope of the incident and the individuals affected. It currently believes the incident is not reasonably likely to have a material impact on its financial condition or results of operations and notes that it maintains cybersecurity insurance that may cover certain losses.
iRhythm Holdings, Inc. disclosed that its wholly owned subsidiary, iRhythm Technologies, Inc., has entered into a binding Settlement Agreement to resolve a previously disclosed putative securities class action in the U.S. District Court for the Northern District of California. The proposed settlement provides for a $45 million payment, inclusive of lead plaintiff’s attorneys’ fees and litigation expenses, in exchange for dismissal with prejudice and a release of all claims against the defendants, without any admission of fault, liability, wrongdoing, or damages. The company expects that a majority of this payment will be covered by its directors and officers insurance policies, after which no further amounts will remain available under those policies for this matter. Because the company excludes non-recurring litigation-related charges from its non-GAAP measures, it does not expect the settlement to affect adjusted EBITDA, adjusted net income (loss), or adjusted operating expenses. The settlement remains subject to court approval.
iRhythm Holdings EVP and Chief Risk Officer Sumi Shrishrimal reported routine equity transactions. She acquired 133 shares of common stock at an average price of $96.815 per share through the company’s 2016 Employee Stock Purchase Plan for the period from December 1, 2025 through May 31, 2026, a transaction exempt from Section 16(b) under Rule 16b-3.
On June 2, 2026, she sold 1,716 shares of common stock at an average price of $108.1891 per share to cover tax withholding and remittance obligations related to vesting Restricted Stock Units. After these transactions, she directly owns 40,287 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two recent transactions in the company’s common stock. He acquired 178 shares at $96.815 per share through the 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 to May 31, 2026, in a transaction exempt from Section 16(b) under Rule 16b-3. He also sold 729 shares at an average price of $108.1893 per share to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units. After these transactions, he directly holds 16,155 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Minang Turakhia reported acquiring 137 shares of common stock, bringing his direct holdings to 55,043 shares. The shares were acquired through the company’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026 and are reported as an exempt award transaction under Rule 16b-3.
iRhythm Holdings, Inc. executive Chad Patterson reported acquiring 177 shares of common stock at $96.815 per share. The shares were purchased through the company’s 2016 Employee Stock Purchase Plan for the period from December 1, 2025 through May 31, 2026.
After this plan-related acquisition, Patterson directly holds 58,341 shares of iRhythm common stock. The filing notes that this transaction is exempt from Section 16(b) under Rule 16b-3 and is being reported on a voluntary basis.
iRhythm Holdings EVP Sean Clinton Freeman acquired additional company stock through a compensation plan. He received 273 shares of common stock on May 29, 2026 at $96.815 per share, increasing his direct holdings to 14,559 shares. The footnote explains this was a voluntary report of shares acquired under iRhythm’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026, and notes the transaction is exempt from Section 16(b) under Rule 16b-3, indicating it is a routine, plan-based acquisition rather than an open-market trade.
iRhythm Holdings, Inc. President and CEO Quentin S. Blackford reported an acquisition of 178 shares of common stock at $96.815 per share. The shares were acquired under the company’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026, in a transaction exempt from Section 16(b) under Rule 16b-3. Following this Plan purchase, he holds 204,333 shares of common stock directly.
iRhythm Holdings director Cathleen Noel Bairey Merz received an equity award of 1,573 shares of Common Stock through restricted stock units. The grant was made at no cash cost to her and is a form of stock-based compensation rather than an open-market purchase.
Each RSU converts into one iRhythm share when it vests. The units vest on the earlier of one year after the grant date or the company’s next annual meeting. After this award, she directly holds 10,546 shares of iRhythm common stock.
Bodaken Bruce G. reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Bruce G. Bodaken received a stock-based award. He was granted 1,573 shares of common stock in the form of restricted stock units at no cash cost. Following this grant, he holds 14,211 shares directly. The RSUs vest on the earlier of one year after grant or the company’s next annual meeting.